Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2014
03/25/2014CA2621988C Quinoline derivatives and use as antitumor agents
03/25/2014CA2620915C Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
03/25/2014CA2604463C 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
03/25/2014CA2597447C Novel tubulin polymerisation inhibitors
03/25/2014CA2594542C Synthesis of inhibitors of p90rsk
03/25/2014CA2577982C Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
03/25/2014CA2524124C Methods for treating cancer using an immunotoxin
03/25/2014CA2484538C Vectors with modified protease-dependent tropism
03/25/2014CA2434672C Sfrp and peptide motifs that interact with sfrp and methods of their use
03/25/2014CA2404448C Genes involved in intestinal inflammatory diseases and use thereof
03/25/2014CA2368369C Docetaxel in combination with rhumab her2 for the treatment of cancers
03/25/2014CA2306492C Human checkpoint kinase, hcds1, compositions and methods
03/21/2014CA2812245A1 Method of inhibiting constitutively active phosphorylated flt3 kinase
03/20/2014WO2014043625A1 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
03/20/2014WO2014043403A1 Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
03/20/2014WO2014043296A1 Aminoisoquinoline derivatives as protein kinase inhibitors
03/20/2014WO2014043208A1 Formulations of enzalutamide
03/20/2014WO2014043084A1 Polymer-polymer composite nanoassemblies and applications thereof
03/20/2014WO2014043068A1 Glucosylceramide synthase inhibitors
03/20/2014WO2014042598A1 Drug therapy for cancer, including multiple myeloma
03/20/2014WO2014042355A1 Pharmaceutical composition for inhibiting cancer or metastasis, containing quassia undulata extract or fraction thereof as active ingredient
03/20/2014WO2014042238A1 Sulfonamide compound
03/20/2014WO2014042226A1 Antigen-specific helper t-cell receptor genes
03/20/2014WO2014042176A1 Method for producing fused-heterocyclic derivative, and production intermediate thereof
03/20/2014WO2014042167A1 Monoclonal antibody against ebag9, hybridoma, and application for monoclonal antibody against ebag9
03/20/2014WO2014042148A1 Cancer marker and application thereof
03/20/2014WO2014041784A1 Ube2t peptides and vaccines containing the same
03/20/2014WO2014041518A1 Thienopyrrole derivatives as itk inhibitors
03/20/2014WO2014041393A1 Combination of compounds derived from gallic acid for the treatment of cancer
03/20/2014WO2014041362A1 Uv radiation cleavable compounds
03/20/2014WO2014041349A1 Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
03/20/2014WO2014041150A1 Contrast agent and its use for imaging
03/20/2014WO2014041144A1 Crystalline compounds
03/20/2014WO2014041142A1 Tablet formulation of a phosphatidylinositol 3-kinase inhibitor
03/20/2014WO2014040938A1 Non-annulated thiophenylamides as inhibitors of fatty acid binding proteini(fabp) 4 and/or 5
03/20/2014WO2014040752A1 Receptor ligand linked cytotoxic molecules
03/20/2014WO2014040555A1 Nitrogen-containing heteroaromatic ring derivative as tyrosine kinase inhibitor
03/20/2014WO2014040549A1 Alkynyl heteroaromatic ring compound and application thereof
03/20/2014WO2014040528A1 Crystallized polymorph of carboxylamide compound l-malate
03/20/2014WO2014040373A1 Pi3k and/or mtor inhibitor
03/20/2014WO2014040366A1 Toxin expelling powder comprising root of buckwheat and preparation process thereof
03/20/2014WO2014040251A1 Isocitrate dehydrogenase 1 as diagnostic and prognostic biomarker and therapeutic target for lung cancer
03/20/2014WO2014040243A1 N-substituted phenyl-n'-substituted heterocyclic urea compound and application thereof as anticancer medicament
03/20/2014WO2014040242A1 3-chloro- and 3-methoxy-n-methyl-2-pyridine carboxamide compound and application thereof as anticancer medicament
03/20/2014WO2014040228A1 Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
03/20/2014WO2014040192A1 Compositions targeting bradykinin receptor b1 for medical imaging of cancer and other disorders
03/20/2014WO2014040143A1 Method of treating cancer
03/20/2014WO2014021693A3 Novel monoclonal antibody which is specifically bound to tm4sf5 protein and use thereof
03/20/2014WO2014021591A3 Novel compound, method for preparing same and pharmaceutical composition comprising same
03/20/2014WO2014016702A3 Humanized forms of monoclonal antibodies to human gnrh receptor
03/20/2014WO2013192274A3 Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
03/20/2014WO2013190292A3 Novel process for preparation of antibody conjugates and novel antibody conjugates
03/20/2014WO2013171777A3 Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network
03/20/2014WO2013152193A3 Methods of treating proliferative disorders with malate or derivatives thereof
03/20/2014WO2013126746A3 Dll3 modulators and methods of use
03/20/2014WO2013019906A9 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
03/20/2014WO2008019491A8 Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein
03/20/2014US20140080736 Tumour marker proteins and uses thereof
03/20/2014US20140079754 Microfabricated nanopore device for sustained release of therapeutic agent
03/20/2014US20140079692 Dosages for treatment with anti-egfr antibodies
03/20/2014US20140079628 Anti-tissue factor antibodies and compositions
03/19/2014EP2708560A1 Antibody specifically recognising transferrin receptor
03/19/2014EP2708534A1 Thiazole compound and preparation method and use thereof
03/19/2014EP2708532A1 4-aminoquinazoline derivatives and uses thereof
03/19/2014EP2708244A1 Contrast agent and its use for imaging.
03/19/2014EP2708243A1 Receptor ligand linked cytotoxic molecules
03/19/2014EP2708238A1 Cytotoxic t cell inducer
03/19/2014EP2708236A1 Tumor treatment
03/19/2014EP2708231A1 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
03/19/2014EP2707372A2 Spiro-oxindole mdm2 antagonists
03/19/2014EP2707359A1 Substituted indazole derivatives active as kinase inhibitors
03/19/2014EP2707102A2 Carbonic anhydrase targeting agents and methods of using same
03/19/2014EP2707031A2 Protein-active agent conjugates and method for preparing the same
03/19/2014EP2707030A1 Cancer treatments
03/19/2014EP2707012A1 Herbal composition for treating cancer
03/19/2014EP2707001A1 Method for treatment of solid malignancies including advanced or metastatic solid malignancies
03/19/2014EP2706996A1 Combination of a statin and a taxane for the treatment of gastric cancer
03/19/2014EP2706993A1 Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
03/19/2014EP2706990A1 Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
03/19/2014CN103649126A Compositions for regulating iron homeostasis and methods of using same
03/19/2014CN103649113A Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
03/19/2014CN103649091A Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
03/19/2014CN103649089A Pyrrolotriazinone derivatives as PI3K inhibitors
03/19/2014CN103649087A Substituted imidazopyridines and intermediates thereof
03/19/2014CN103649085A Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
03/19/2014CN103649074A Substituted azaheterocycles for the treatment of cancer
03/19/2014CN103649073A 17alpha-hydroxylase/c17,20-lyase inhibitors
03/19/2014CN103649053A Aminomethyl quinolone compounds
03/19/2014CN103649033A Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars
03/19/2014CN103649031A Prenylated hydroxystilbenes
03/19/2014CN103648588A Compounds for the treatment of cancers associated with human papillomavirus
03/19/2014CN103648532A Novel maytansinoid derivatives with peptide linker and conjugates thereof
03/19/2014CN103648530A Protein-active agent conjugates and method for preparing the same
03/19/2014CN103648529A Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects
03/19/2014CN103648513A Yeast-brachyury immunotherapeutic compositions
03/19/2014CN103642898A Mutations in oas1 genes
03/19/2014CN103642887A Preparation method for celastrol derivatives, products and application thereof
03/19/2014CN103642812A Nile tilapia apoptosis factor FasL gene and applications thereof
03/19/2014CN103642491A Strong signal and low toxicity composite nanometer material and preparation method thereof
03/19/2014CN103641925A Covalent polycompound of water-soluble polysaccharide and taxane compound, and preparation method and medical application of covalent polycompound
1 ... 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 ... 2211